Esophageal CancerNCT06343597
Volume Outcome Relationships and Effects
An observational study of Esophageal Cancer, run by Methodist Health System at 1 site in United States.
Trial summary
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Esophageal Cancer
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jun 2020to 15 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The purpose of the study is to evaluate the outcomes of esophageal cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities.
Who may be able to join
- esophageal cancer
Who cannot join
- No esophageal cancer
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Methodist Richardson Medical Center
Richardson, Texas, 75082
Crystee Cooper, DHEd, 2149471280, clinicalresearch@mhd.com
Zaid Haddadin, MS, 2149471280, clinicalresearch@mhd.com
About this study
Official title: Volume Outcome Relationships and Effects of Adjuvant and Neoadjuvant Therapy in Mortality in Esophageal Cancer
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
Read the detailed description
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
The relationship between volume and outcomes has been proven in pancreatic cancer. Similar to pancreatic cancer, esophageal cancer historically has a bad prognosis. Esophageal cancer is typically asymptomatic, resulting in an advanced stage at the time of diagnosis. Additionally, it also has a significantly high morbidity and mortality. Therefore, it is crucial to determine volume-outcome relationships in esophageal cancer. This study aims to elucidate what these findings may entail by evaluating the impact that the volume-outcome relationship has on treatment assessment in esophageal cancer patients.
The purpose of the study is to evaluate the outcomes of esophageal cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities. Furthermore, this paper will assess the outcomes of neoadjuvant and adjuvant therapy in esophageal cancer.
- Conditions
- Esophageal Cancer
- Medical subject headings
- Esophageal Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Esophageal Cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities
Retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with Esophageal Cancer than low-volume facilities
Measured: through study completion, up to 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2024
- Study start15 Jun 2020
- Primary completion15 Jun 2027 (estimated)
- Study completion15 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophageal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dhiresh Jeyarajah, MD, Principal investigator, Methodist Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06343597
- Sponsor's protocol ID
- 037.HPB.2020.R
- Status last verified
- Jan 2026
- First submitted
- 27 Apr 2022
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Volume Outcome Relationships and Effects of Adjuvant and Neoadjuvant Therapy in Mortality in Esophageal Cancer
- ClinicalTrials.gov ID
- NCT06343597
- Acronym / sponsor ID
- 037.HPB.2020.R
- Conditions
- Esophageal Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Methodist Health SystemUniversity, hospital or other
- Study start
- 15 Jun 2020 (actual)
- Primary completion
- 15 Jun 2027 (estimated)
- Study completion
- 15 Jun 2028 (estimated)
- First posted
- 2 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
Detailed description
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
The relationship between volume and outcomes has been proven in pancreatic cancer. Similar to pancreatic cancer, esophageal cancer historically has a bad prognosis. Esophageal cancer is typically asymptomatic, resulting in an advanced stage at the time of diagnosis. Additionally, it also has a significantly high morbidity and mortality. Therefore, it is crucial to determine volume-outcome relationships in esophageal cancer. This study aims to elucidate what these findings may entail by evaluating the impact that the volume-outcome relationship has on treatment assessment in esophageal cancer patients.
The purpose of the study is to evaluate the outcomes of esophageal cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities. Furthermore, this paper will assess the outcomes of neoadjuvant and adjuvant therapy in esophageal cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The purpose of the study is to evaluate the outcomes of esophageal cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities.
Key inclusion criteria (1 listed)
- esophageal cancer
Key exclusion criteria (1 listed)
- No esophageal cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Esophageal Cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities
Time frame: through study completion, up to 18 months
Retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with Esophageal Cancer than low-volume facilities
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
Related trials for Esophageal Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
RecruitingObservational study
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Esophageal Cancer, Head and Neck Cancer
RecruitingPhase 1
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Colorectal Cancer, Non-Small Cell Lung Cancer
RecruitingPhase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Active, not recruitingPhase 1
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Advanced or Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dhiresh Jeyarajah, MD principal investigator
Methodist Health System
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Esophageal Cancer, run by Methodist Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Crystee Cooper, DHEd (214-947-1280, clinicalresearch@mhd.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Esophageal Cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities (time frame: through study completion, up to 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.